drugset / Trial / NCT06067581
the Safety and Efficacy of SENL103 Autologous T Cell Injection
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety and efficacy of SENL103 cells in the treatment of patients with recurrent or refractory plasma cell blood tumors.
Timeline
- Start
- 2023-08-21
- Primary completion
- 2025-08
- Completion
- 2025-08
Outcome
Met primary endpoint
release “结果显示，BCMA CAR-T细胞输注后3个月的总体缓解率（ORR）达到100%，深度缓解率（CR+VGPR）81.5%” senlangbio.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SENL103 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | SENL103 | Cell therapy | 2e+06 cells/kg | Intravenous |
| Subject | SENL103 | Cell therapy | 3e+06 cells/kg | Intravenous |